Atrionatriuretic Peptide Improves Left Ventricular Function After Myocardial Global Ischemia-Reperfusion in Hypoxic Hearts

Yasuhiro Fujii, Kozo Ishino, Tomoko Tomii, Hitoshi Kanamitsu, Yasufumi Fujita, Hideya Mitsui, Shunji Sano

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Atrionatriuretic peptide (ANP) is reported to be useful for attenuating myocardial ischemia-reperfusion injury and improving left ventricular function after reperfusion. However, ANP may be either ineffectual or harmful in cases where the myocardium has been chronically hypoxic since birth. This can be a result of the concomitant high levels of cyclic guanosine monophosphate (cGMP) produced within the myocardium. This study aimed to verify the validity of using ANP to improve left ventricular function after myocardial ischemia-reperfusion injury. For this purpose, a cyanotic congenital disease model that was developed using isolated rat hearts was used. Hearts were obtained from Sprague-Dawley rats that were housed from birth until 6 weeks of age either in a hypoxic environment with 13-14% FiO 2 (hypoxic group) or in ambient air (normoxic group). These hearts were subjected to 30min of normothermic global ischemia followed by 30min of reperfusion using the Langendorff technique. Left ventricular functional recovery in hearts administered ANP (0.1μM) into the reperfusion solution was compared with those hearts that were not administered ANP in both hypoxic (without ANP: n=6, with ANP: n=6, with ANP and HS-142-1[an antagonist of ANP]: n=6) and normoxic hearts (without ANP: n=6, with ANP: n=6). In the hypoxic hearts, ANP administration improved the percent recovery of the left ventricular developed pressure (76.3±9.2% without ANP vs. 86.9±6.7% with ANP), maximum first derivative of the left ventricular pressure (82.4±1.1% without ANP vs. 95.8±6.5% with ANP), and heart rate (85.6±4.7% without ANP vs. 96.1±5.2% with ANP) after reperfusion. The improvement and recovery of these cardiac functions were closely related to significantly increased levels of postischemic cGMP release after ANP administration. The effect of ANP was blocked by HS-142-1. The improvements observed in the hypoxic group were similar to those found in the normoxic group. ANP administration during reperfusion improved left ventricular function after myocardial acute global ischemia-reperfusion equally in both the chronically hypoxic and age-matched normoxic groups.

Original languageEnglish
Pages (from-to)379-386
Number of pages8
JournalArtificial Organs
Volume36
Issue number4
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Left Ventricular Function
Peptides
Reperfusion
Myocardial Ischemia
Myocardial Reperfusion Injury
Cyclic GMP
Ventricular Pressure
Reperfusion Injury
Recovery
Rats
Myocardium
Ischemia
Parturition
Recovery of Function

Keywords

  • Atrial natriuretic factor
  • Hypoxia
  • Myocardium
  • Reperfusion

ASJC Scopus subject areas

  • Biomaterials
  • Biomedical Engineering
  • Bioengineering
  • Medicine (miscellaneous)

Cite this

Atrionatriuretic Peptide Improves Left Ventricular Function After Myocardial Global Ischemia-Reperfusion in Hypoxic Hearts. / Fujii, Yasuhiro; Ishino, Kozo; Tomii, Tomoko; Kanamitsu, Hitoshi; Fujita, Yasufumi; Mitsui, Hideya; Sano, Shunji.

In: Artificial Organs, Vol. 36, No. 4, 04.2012, p. 379-386.

Research output: Contribution to journalArticle

Fujii, Yasuhiro ; Ishino, Kozo ; Tomii, Tomoko ; Kanamitsu, Hitoshi ; Fujita, Yasufumi ; Mitsui, Hideya ; Sano, Shunji. / Atrionatriuretic Peptide Improves Left Ventricular Function After Myocardial Global Ischemia-Reperfusion in Hypoxic Hearts. In: Artificial Organs. 2012 ; Vol. 36, No. 4. pp. 379-386.
@article{e7513dec82fe4be8b42f5ec11b67a187,
title = "Atrionatriuretic Peptide Improves Left Ventricular Function After Myocardial Global Ischemia-Reperfusion in Hypoxic Hearts",
abstract = "Atrionatriuretic peptide (ANP) is reported to be useful for attenuating myocardial ischemia-reperfusion injury and improving left ventricular function after reperfusion. However, ANP may be either ineffectual or harmful in cases where the myocardium has been chronically hypoxic since birth. This can be a result of the concomitant high levels of cyclic guanosine monophosphate (cGMP) produced within the myocardium. This study aimed to verify the validity of using ANP to improve left ventricular function after myocardial ischemia-reperfusion injury. For this purpose, a cyanotic congenital disease model that was developed using isolated rat hearts was used. Hearts were obtained from Sprague-Dawley rats that were housed from birth until 6 weeks of age either in a hypoxic environment with 13-14{\%} FiO 2 (hypoxic group) or in ambient air (normoxic group). These hearts were subjected to 30min of normothermic global ischemia followed by 30min of reperfusion using the Langendorff technique. Left ventricular functional recovery in hearts administered ANP (0.1μM) into the reperfusion solution was compared with those hearts that were not administered ANP in both hypoxic (without ANP: n=6, with ANP: n=6, with ANP and HS-142-1[an antagonist of ANP]: n=6) and normoxic hearts (without ANP: n=6, with ANP: n=6). In the hypoxic hearts, ANP administration improved the percent recovery of the left ventricular developed pressure (76.3±9.2{\%} without ANP vs. 86.9±6.7{\%} with ANP), maximum first derivative of the left ventricular pressure (82.4±1.1{\%} without ANP vs. 95.8±6.5{\%} with ANP), and heart rate (85.6±4.7{\%} without ANP vs. 96.1±5.2{\%} with ANP) after reperfusion. The improvement and recovery of these cardiac functions were closely related to significantly increased levels of postischemic cGMP release after ANP administration. The effect of ANP was blocked by HS-142-1. The improvements observed in the hypoxic group were similar to those found in the normoxic group. ANP administration during reperfusion improved left ventricular function after myocardial acute global ischemia-reperfusion equally in both the chronically hypoxic and age-matched normoxic groups.",
keywords = "Atrial natriuretic factor, Hypoxia, Myocardium, Reperfusion",
author = "Yasuhiro Fujii and Kozo Ishino and Tomoko Tomii and Hitoshi Kanamitsu and Yasufumi Fujita and Hideya Mitsui and Shunji Sano",
year = "2012",
month = "4",
doi = "10.1111/j.1525-1594.2011.01358.x",
language = "English",
volume = "36",
pages = "379--386",
journal = "Artificial Organs",
issn = "0160-564X",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Atrionatriuretic Peptide Improves Left Ventricular Function After Myocardial Global Ischemia-Reperfusion in Hypoxic Hearts

AU - Fujii, Yasuhiro

AU - Ishino, Kozo

AU - Tomii, Tomoko

AU - Kanamitsu, Hitoshi

AU - Fujita, Yasufumi

AU - Mitsui, Hideya

AU - Sano, Shunji

PY - 2012/4

Y1 - 2012/4

N2 - Atrionatriuretic peptide (ANP) is reported to be useful for attenuating myocardial ischemia-reperfusion injury and improving left ventricular function after reperfusion. However, ANP may be either ineffectual or harmful in cases where the myocardium has been chronically hypoxic since birth. This can be a result of the concomitant high levels of cyclic guanosine monophosphate (cGMP) produced within the myocardium. This study aimed to verify the validity of using ANP to improve left ventricular function after myocardial ischemia-reperfusion injury. For this purpose, a cyanotic congenital disease model that was developed using isolated rat hearts was used. Hearts were obtained from Sprague-Dawley rats that were housed from birth until 6 weeks of age either in a hypoxic environment with 13-14% FiO 2 (hypoxic group) or in ambient air (normoxic group). These hearts were subjected to 30min of normothermic global ischemia followed by 30min of reperfusion using the Langendorff technique. Left ventricular functional recovery in hearts administered ANP (0.1μM) into the reperfusion solution was compared with those hearts that were not administered ANP in both hypoxic (without ANP: n=6, with ANP: n=6, with ANP and HS-142-1[an antagonist of ANP]: n=6) and normoxic hearts (without ANP: n=6, with ANP: n=6). In the hypoxic hearts, ANP administration improved the percent recovery of the left ventricular developed pressure (76.3±9.2% without ANP vs. 86.9±6.7% with ANP), maximum first derivative of the left ventricular pressure (82.4±1.1% without ANP vs. 95.8±6.5% with ANP), and heart rate (85.6±4.7% without ANP vs. 96.1±5.2% with ANP) after reperfusion. The improvement and recovery of these cardiac functions were closely related to significantly increased levels of postischemic cGMP release after ANP administration. The effect of ANP was blocked by HS-142-1. The improvements observed in the hypoxic group were similar to those found in the normoxic group. ANP administration during reperfusion improved left ventricular function after myocardial acute global ischemia-reperfusion equally in both the chronically hypoxic and age-matched normoxic groups.

AB - Atrionatriuretic peptide (ANP) is reported to be useful for attenuating myocardial ischemia-reperfusion injury and improving left ventricular function after reperfusion. However, ANP may be either ineffectual or harmful in cases where the myocardium has been chronically hypoxic since birth. This can be a result of the concomitant high levels of cyclic guanosine monophosphate (cGMP) produced within the myocardium. This study aimed to verify the validity of using ANP to improve left ventricular function after myocardial ischemia-reperfusion injury. For this purpose, a cyanotic congenital disease model that was developed using isolated rat hearts was used. Hearts were obtained from Sprague-Dawley rats that were housed from birth until 6 weeks of age either in a hypoxic environment with 13-14% FiO 2 (hypoxic group) or in ambient air (normoxic group). These hearts were subjected to 30min of normothermic global ischemia followed by 30min of reperfusion using the Langendorff technique. Left ventricular functional recovery in hearts administered ANP (0.1μM) into the reperfusion solution was compared with those hearts that were not administered ANP in both hypoxic (without ANP: n=6, with ANP: n=6, with ANP and HS-142-1[an antagonist of ANP]: n=6) and normoxic hearts (without ANP: n=6, with ANP: n=6). In the hypoxic hearts, ANP administration improved the percent recovery of the left ventricular developed pressure (76.3±9.2% without ANP vs. 86.9±6.7% with ANP), maximum first derivative of the left ventricular pressure (82.4±1.1% without ANP vs. 95.8±6.5% with ANP), and heart rate (85.6±4.7% without ANP vs. 96.1±5.2% with ANP) after reperfusion. The improvement and recovery of these cardiac functions were closely related to significantly increased levels of postischemic cGMP release after ANP administration. The effect of ANP was blocked by HS-142-1. The improvements observed in the hypoxic group were similar to those found in the normoxic group. ANP administration during reperfusion improved left ventricular function after myocardial acute global ischemia-reperfusion equally in both the chronically hypoxic and age-matched normoxic groups.

KW - Atrial natriuretic factor

KW - Hypoxia

KW - Myocardium

KW - Reperfusion

UR - http://www.scopus.com/inward/record.url?scp=84859621961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859621961&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1594.2011.01358.x

DO - 10.1111/j.1525-1594.2011.01358.x

M3 - Article

C2 - 22040266

AN - SCOPUS:84859621961

VL - 36

SP - 379

EP - 386

JO - Artificial Organs

JF - Artificial Organs

SN - 0160-564X

IS - 4

ER -